TY - JOUR
T1 - Therapy of endocrine disease
T2 - Treatment of malignant pheochromocytoma and paraganglioma
AU - Baudin, Eric
AU - Habra, Mouhammed Amir
AU - Deschamps, Frederic
AU - Cote, Gilbert
AU - Dumont, Frederic
AU - Cabanillas, Maria
AU - Arfi-Roufe, J.
AU - Berdelou, A.
AU - Moon, Bryan
AU - Ghuzlan, Abir Al
AU - Patel, Shreyaskumar
AU - Leboulleux, Sophie
AU - Jimenez, Camilo
N1 - Publisher Copyright:
© 2014 European Society of Endocrinology Printed in Great Britain.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - Metastatic pheochromocytomas and paragangliomas (MPPs) present clinicianswith three major challenges: scarcity, complexity of characterization, and heterogeneous behavior and prognosis. As with the treatment for all neuroendocrine tumors, the control of hormonal symptoms and tumor growth is the main therapeutic objective in MPP patients. A significant number of MPP patients still die from uncontrolled hormone secretion. In addition, the management of MPPs remains palliative. Steps forward include proper characterization of MPP patients at large cancer referral centerswithmultidisciplinary teams; improved strategies to stratify patients prognostically; and implementation of trials within national and international networks. Progress in the molecular characterization and staging of MPPs constitutes the basis for significant treatment breakthroughs.
AB - Metastatic pheochromocytomas and paragangliomas (MPPs) present clinicianswith three major challenges: scarcity, complexity of characterization, and heterogeneous behavior and prognosis. As with the treatment for all neuroendocrine tumors, the control of hormonal symptoms and tumor growth is the main therapeutic objective in MPP patients. A significant number of MPP patients still die from uncontrolled hormone secretion. In addition, the management of MPPs remains palliative. Steps forward include proper characterization of MPP patients at large cancer referral centerswithmultidisciplinary teams; improved strategies to stratify patients prognostically; and implementation of trials within national and international networks. Progress in the molecular characterization and staging of MPPs constitutes the basis for significant treatment breakthroughs.
UR - http://www.scopus.com/inward/record.url?scp=84907220377&partnerID=8YFLogxK
U2 - 10.1530/EJE-14-0113
DO - 10.1530/EJE-14-0113
M3 - Review article
C2 - 24891137
AN - SCOPUS:84907220377
SN - 0804-4643
VL - 171
SP - R111-R122
JO - European Journal of Endocrinology
JF - European Journal of Endocrinology
IS - 3
ER -